TY - JOUR
T1 - Limited Clinical Benefit from Trastuzumab in Recurrent Endometrial Cancer Two Case Reports
AU - Vandenput, I.
AU - Vanden Bempt, I.
AU - Leunen, K.
AU - Neven, P.
AU - Berteloot, P.
AU - Moerman, P.
AU - Vergote, I.
AU - Amant, F.
PY - 2008
Y1 - 2008
N2 - Background: It is hypothesized that the HER-2/neu receptor could be used for targeted therapy in recurrent endometrial cancer. Cases: A patient with type II endometrial cancer (serous), showing strong HER-2/neu overexpression and gene amplification in both primary and recurrent tumor, received single-agent trastuzumab (3 x weekly, 8 mg/kg loading, 6 mg/kg maintenance dose). Because of progression after 4 cycles, weekly paclitaxel-trastuzumab (80 mg/m(2) paclitaxel; trastuzumab 4 mg/kg loading, 2 mg/kg maintenance dose) was initiated. However, progressive disease was also noted after 11 weeks of combined treatment. A second patient, with recurrent type II endometrial cancer (grade III endometrioid), had HER-2/neu gene amplification in the primary tumor. However, biopsy from a lung metastasis 3 years later appeared to be HER-2/neu-negative. Conclusion: Based on lack of response and changes in tumor biology, trastuzumab was of little clinical value in 2 cases of recurrent type II endometrial cancer. This report underscores the importance of reassessment of a recurrent tumor before initiating targeted treatment. Copyright (C) 2008 S. Karger AG, Basel
AB - Background: It is hypothesized that the HER-2/neu receptor could be used for targeted therapy in recurrent endometrial cancer. Cases: A patient with type II endometrial cancer (serous), showing strong HER-2/neu overexpression and gene amplification in both primary and recurrent tumor, received single-agent trastuzumab (3 x weekly, 8 mg/kg loading, 6 mg/kg maintenance dose). Because of progression after 4 cycles, weekly paclitaxel-trastuzumab (80 mg/m(2) paclitaxel; trastuzumab 4 mg/kg loading, 2 mg/kg maintenance dose) was initiated. However, progressive disease was also noted after 11 weeks of combined treatment. A second patient, with recurrent type II endometrial cancer (grade III endometrioid), had HER-2/neu gene amplification in the primary tumor. However, biopsy from a lung metastasis 3 years later appeared to be HER-2/neu-negative. Conclusion: Based on lack of response and changes in tumor biology, trastuzumab was of little clinical value in 2 cases of recurrent type II endometrial cancer. This report underscores the importance of reassessment of a recurrent tumor before initiating targeted treatment. Copyright (C) 2008 S. Karger AG, Basel
U2 - https://doi.org/10.1159/000161568
DO - https://doi.org/10.1159/000161568
M3 - Article
C2 - 18843183
SN - 0378-7346
VL - 67
SP - 46
EP - 48
JO - Gynecologic and Obstetric Investigation
JF - Gynecologic and Obstetric Investigation
IS - 1
ER -